Education
About Us
Working with TipRanks
Follow Us
InspireMD (NSPR)
NASDAQ:NSPR
NSPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.81 - $3.80
Previous CloseN/A
Volume8.46K
Average Volume (3M)76.36K
Market Cap
$80.16M
Enterprise Value$90.46M
Total Cash (Recent Filing)$9.62M
Total Debt (Recent Filing)$1.45M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 20, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding29,689,857
10 Day Avg. Volume63,154
30 Day Avg. Volume76,355
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.61
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit60.06
Enterprise Value/Ebitda-2.72
Forecast
1Y Price Target
$5.00Price Target Upside85.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
InspireMD News
PremiumCompany Announcements
InspireMD Inc. Reports 2024 Financial Results and Strategic Progress
PremiumCompany Announcements
InspireMD’s Earnings Call: Cautious Optimism Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialInspireMD could be an attractive add-on for Boston Scientific or other big MedTech cardiovascular players.
FDA ApprovalInspireMD is approaching its most important catalyst, FDA approval of its CGuard carotid artery stent.
Market PotentialInspireMD can quickly build a $50M CGuard business and a $25M SwitchGuard business by 2028.
Bears Say
CompetitionThe 30-day DSMI rate for CGuard is sub-1% vs. others from 2.3% to as high as 8.3%. This data should support a quick share shift to CGuard within the transfemoral carotid artery stenting (TF-CAS) market.
---
Ownership Overview
29.35% Insiders
0.07% Mutual Funds
12.78% Other Institutional Investors
57.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $1.81 and its highest was $3.80 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $80.16M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is May 20, 2025 which is in 49 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on Mar 12, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.005.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.2.
How many shares outstanding does InspireMD have?
InspireMD has 29,689,857 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 0.717%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
---
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (85.19% Upside)
$5.00 (85.19% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.92%
12-Months-Change
Fundamentals
Return on Equity
-84.68%
Trailing 12-Months
Asset Growth
-1.75%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
---
NSPR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong revenue growth and clinical trial success for CGuard products, alongside anticipated US market expansion. However, increased operating expenses, decreased gross profit margins, and a higher net loss create financial challenges. The sentiment reflects cautious optimism with significant expectations from the US market entry.Read More>---
NSPR Stock 12 Month Forecast
Average Price Target
$5.00
▲(85.19% Upside)
Technical Analysis
Best Analysts Covering NSPR
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+10.17%
assigned a buy rating 7 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +10.17% per trade.
---